Most material SEC filings — August 14, 2026

VerifyMe reported Q2 2026 revenue of $1.9M (down 58% YoY from $4.5M), driven by September 2025 carrier partner termination and ProActive customer loss. Net loss widened to ($0.5M) from ($0.3M); Adjusted EBITDA fell to $0.0M from $0.3M. Cash position of $5.1M ($4.7M working capital) against $8.0M market cap; company is burning cash while pursuing a merger.

Quince completed a stock-for-stock merger with Orphai Therapeutics on May 18, 2026, acquiring LAM-001 (inhaled rapamycin) for PH-ILD, BOS, and SAPH. Concurrent private placement raised $115M gross ($103.6M net), with potential $83M additional from warrant exercise. Cash position is $116M as of June 30, 2026, expected to fund operations through end of 2028. Q2 2026 net loss was $75.5M ($12.31/share on 978,022 shares); LAM-001 Phase 2b PH-ILD data expected Q1 2028, Phase 2 BOS data expected Q1 2027.

VirTra reported H1 2026 revenue of $9.2M (down 35% YoY from $14.1M) and net loss of $1.6M (vs. $1.4M profit YoY). Q2 revenue was $5.8M (down 17% YoY). Backlog stood at $24.9M ($13.2M capital, $3.8M service, $7.9M STEP). The company acquired an Orlando dual-building campus and was accepted into the U.S. Army Marketplace across three capability areas. Adjusted EBITDA swung to negative $0.4M for H1 (vs. positive $2.4M YoY).

Q2 2026: Digi Power X generated $6.6M revenue (including $1.1M from GPU rental in five weeks), net loss $14.4M, positive Adjusted EBITDA $3.3M. The company secured a 10-year AI data center contract worth $1.1B (~$140M annualized), expandable to $2.5B. Cash position $150M (post-August 14), zero debt; targets $250M–$300M annualized revenue by Q3 2027 from Alabama Tier III data center (40 MW by Mar 2027) and GPU platform expansion (10 MW planned in 2027). Also holds ~48% of subsidiary USDC (valued $125M pre-money in Q2 2026).

TuHURA Biosciences (market cap ~$111M) announced a $50 million term credit facility from its largest shareholder in April 2026, bearing 12% annual interest with 5-year maturity (April 2031). The company has drawn $5.7M to date ($2.15M after June 30, 2026) and holds $1.0M cash at Q2 2026 quarter-end. The facility extends runway into 2028 and supports Phase 1b/2 trials for TBS-2025 (VISTA inhibitor in AML) and ongoing Phase 3 development of IFx-2.0 (innate immune agonist for Merkel cell carcinoma).

LanzaTech reported Q2 2026 revenue of $9.0M (flat YoY) but net income of $184.3M, primarily from a $208.1M non-cash unrealized gain on its 8.38% stake in Shougang LanzaTech (SGLT), which IPO'd on Hong Kong Exchange in June at $750M valuation, later rising to ~$1.32B. Operating expenses fell 67% to $11.7M from $35.1M YoY due to headcount reductions and cost optimization. Adjusted EBITDA loss improved to $(7.6)M from $(29.7)M. Cash increased to $48.9M from $17.1M after $50M equity raise.

Galectin Therapeutics' Chairman Richard Uihlein converted $105.8M in debt ($91.0M principal + $14.8M accrued interest) into 34,376,167 common shares, effective July 31, 2026, eliminating five of six credit facilities. Simultaneously, the FDA agreed on Phase 3 trial design for belapectin in MASH cirrhosis with portal hypertension; the company expects to submit the registrational protocol in Q3 2026. Cash position: $13.2M as of June 30, 2026, with $10M additional credit available.

PMV Pharmaceuticals completed enrollment of platinum-resistant/refractory ovarian cancer patients in the PYNNACLE Phase 2 monotherapy trial for rezatapopt (PC14586), a p53 Y220C reactivator. The company plans to submit an NDA for accelerated approval in Q1 2027. Cash position declined to $79.4M (June 30, 2026) from $112.9M (Dec 31, 2025), providing runway through Q2 2027; operating cash burn for H1 2026 was $34.3M.

Outlook Therapeutics obtained FDA approval for LYTENAVA (bevacizumab-vikg), an ophthalmic bevacizumab for wet AMD, and is planning U.S. commercial launch by end of 2026. Management projects potential peak sales exceeding $500M annually by 2030. Post-quarter (August 2026), the company closed a public offering of 55.6M shares and 55.6M warrants at $0.99/share for ~$51.1M net proceeds. Q3 FY2026 net loss was $20.3M ($0.15/share); adjusted net loss $10.9M ($0.09/share). Cash on hand at quarter-end was $11.2M.

Aptevo reported Q2 2026 cash of $9.8M (matching entire market cap). Mipletamig showed 87% clinical benefit rate and 81% remission rate in 31 frontline AML patients in Phase 1b RAINIER trial; company targets Phase 2 dose selection by year-end 2026 and regulatory interaction in Q1 2027. Non-dilutive $1.5M grant from Andy Hill Cancer Research Endowment funds APVO451 trispecific development. Aptevo entered 50/50 collaboration with Niowave for up to three radiopharmaceutical programs; Niowave made equity investment at closing representing 7.9% stake with potential to reach 19.99%.

FDA granted accelerated approval to TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for unresectable advanced cutaneous melanoma on August 6, 2026; Replimune completed $150M financing ($141M net proceeds received in August 2026) to fund commercial launch and IGNYTE-3 confirmatory trial; Michelle DiNapoli appointed Chief Commercial Officer effective August 18, 2026, bringing 25+ years oncology commercialization experience.

Aptevo Research and Development LLC (Aptevo's subsidiary) entered into a 50/50 cost-sharing collaboration with Niowave, Inc. dated May 25, 2026, to develop oncology radiopharmaceutical products combining Aptevo's proprietary molecules with Niowave's Actinium-225 radioisotopes. Concurrently, Niowave purchased 98,522 shares of Aptevo common stock at an initial price (price redacted [***]), with rights to purchase up to 150,574 additional shares during a 3-year exercise period, capped at 19.99% beneficial ownership and $8.00 warrants. Development costs split equally; revenue from third-party licensees allocated 50/50 (or per cost-share ratio if unequal). Terminating party receives 2–8% royalty on net sales depending on development stage at exit.

Mithaq Capital SPC transferred 500,000 restricted shares of Children's Place common stock to Muhammad Asif Seemab (Executive Vice-Chairman, President, Interim CEO) on August 11, 2026. Vesting occurs in three tranches of ~166,667 shares each upon market capitalization milestones: $265M (Tranche 1), $400M (Tranche 2), and $600M (Tranche 3). Unvested shares forfeit after 5 years unless extended. Current company market value is ~$38M.

Professional Diversity Network (market cap ~$5.3M) completed the divestiture of NAPW Network and IAW, Inc. in July 2026 to focus on core businesses. Q2 2026 revenues declined $460K (28%) to $1.181M versus $1.641M in Q2 2025, driven by 33.8% decline in TalentAlly recruitment services ($300K) and 21.3% drop in RemoteMore software development ($142K). Net loss from continuing operations widened to $1.716M (Q2 2026) from $492K (Q2 2025), primarily due to $1.156M in amortization of 28 musical work copyrights acquired since September 2025. Working capital deficit improved to $0.9M from $4.0M at year-end 2025.

MySize (NASDAQ: MYSZ, $4M market cap) reported Q2 2026 revenue of $3.07M (+53% YoY) and H1 revenue of $5.46M (+57% YoY). However, net loss expanded to $1.75M in Q2 (vs. $450K prior year) and gross margin compressed to 31.7% (vs. 56.0%) due to higher e-commerce mix. Management now prioritizes contribution margin improvement, operating leverage, and cash efficiency over growth; Q2 operating cash burn was $1.97M H1 (improved from $2.31M prior year). Company held only $453K cash as of June 30, 2026.

Moleculin reported positive interim Phase 2/3 MIRACLE trial data showing complete remission (CR) rates of 43% and 36% in two Annamycin arms versus 12% control in relapsed/refractory AML (n=45). The company raised $9.3M in post-quarter financing and expects cash to fund operations into Q1 2027. Part A enrollment (90 patients) targeted for September 2026 completion with data readout December 2026–February 2027; Part B initiation expected H1 2027.

EDAP TMS S.A. agreed to sell 8,425,000 ADSs (representing ordinary shares) at $4.75 per ADS to underwriters TD Securities and Mizuho Securities on August 11, 2026, with an option to purchase an additional 1,263,750 ADSs at the same price. Gross proceeds approximately $40.0M before $2.4M underwriting discount ($0.285/ADS), net ~$37.6M. The company is a French medical device company with market cap ~$61.8M, making this capital raise ~65% of current market value.

On June 10, 2026, Neumora Therapeutics amended its Loan and Security Agreement with K2 HealthVentures LLC. Key changes: (1) relaxed financial covenant from 105% to 110% of total senior debt obligations; (2) extended amortization commencement date to May 1, 2029; (3) paid a non-refundable amendment fee of $445,000. The company also released all prior claims against lenders. Specific dollar amounts and share counts beyond the $445K fee are redacted as confidential.

Beneficient (NASDAQ: BENF, ~$8.6M market cap) closed two primary capital commitments totaling >$16M in Q1 FY2027 (ended June 30, 2026) and signed its first collateral management services engagement with a Texas state-chartered bank for recurring fee revenue on alternative asset-backed financing. Operating expenses fell 84.3% to $12.5M (vs. $80.0M prior year, which included $62.8M loss contingency accrual); excluding one-time accruals, expenses declined 37.4%. Loan portfolio grew to $186.0M (collateralized by $212.5M in investments); company raised $3.8M post-quarter via two promissory notes. Q1 net loss attributable to common shareholders: $6.8M (vs. $65.1M loss in Q1 FY2026).

Lantern Pharma (market cap ~$33.9M) separated Open Medicine AI (OMAI) as a wholly-owned subsidiary with executed commercial licenses; OMAI intends to raise outside capital and eventually list publicly. LP-300 HARMONIC trial showed median 8.9-month progression-free survival in 9 EGFR L858R patients completing 6 cycles (vs. 8.4 months across 16 total L858R patients, hazard ratio 0.37); FDA approved protocol amendments to focus enrollment on L858R patients and extend treatment from 6 to 8 cycles. LP-184 gained EMA clearance for Phase 1b/2 bladder cancer trial at Rigshospitalet, Denmark, and FDA cleared TNBC trial initiation. Cash position: $7.4M as of June 30, 2026 (down from $10.1M Dec 31, 2025); Q2 operating loss decreased 25% YoY to $3.5M; net loss $7.1M (Q2) including $3.6M non-cash warrant expense.

Western Union received approval from New York's NYDFS for its acquisition of Intermex (NASDAQ: IMXI), subject to commitments on remittance services and locations in New York. However, on August 13, 2026, California's DFPI suspended its previously granted approval extension, citing need to further review the transaction's state impact after six months. Both parties committed to resolving California's concerns and closing promptly upon reinstatement.

Director Troim Tor Olav (BORR) bought 1.5M shares (~$6.0M) on the open market (5.0% of holdings). Open-market insider purchase — historically a bullish signal.

Teamshares (market cap ~$246M) reported Q2 2026 revenue of $148.7M (+20% YoY) and net income of $9.5M (+$22.4M YoY, driven by non-cash fair-value gains of $24.9M on earnout liabilities). Adjusted EBITDA grew 166% to $9.6M; LTM Pro Forma Adjusted EBITDA reached $21.2M. The company completed its Nasdaq IPO on June 23, 2026, raising $132.4M gross proceeds (with concurrent PIPE), repaid $54.5M total debt, and has $30M in annual EBITDA under non-binding LOIs (10 businesses) against its $40M 2026 acquisition target. Management reaffirmed full-year 2026 guidance of $60M Pro Forma Adjusted EBITDA, contingent on completing financing for acquisitions.

Q2 2026 revenue reached $97.2M (up 146% YoY from $39.5M); company acquired Hope Concrete, Nelson Bros., and ABC Block Company during Q2, adding operations in Texas, Louisiana, Arkansas, and Mississippi. Net loss was $37.1M (vs. $325K loss in Q2 2025), driven by $26.9M non-cash charge related to business combination and $12.2M acquisition costs. Company maintains 2026 guidance: revenue $420M–$480M, Adjusted EBITDA $68M–$93M.

Rank One Computing (Nasdaq: ROC) reported Q2 2026 revenue of $5.1M, up 100% sequentially from Q1's $2.5M, driven by a newly awarded $4.9M R&D contract with the U.S. Department of War. Product revenue declined 26% YoY to $2.1M due to completion of a ROC Watch deployment, but Vision AI products showed strong growth: ROC SDK +84% YoY to $1.6M, ROC ABIS +723% YoY to $164K, ROC Evidence achieved first commercial revenue of $18K ahead of plan. Gross margin improved to 90% from 80% YoY. Company entered a definitive agreement to acquire Zuccaro Technical Consulting LLC (digital forensics) for Q3 2026 closing. Cash position: $11.9M with no debt; company IPO'd in February 2026.